→ Free Ebook: The Ultimate Guide to Investing in the Stock Market (From Vector Best)
Cigna Co. (NYSE:CI – Get Rating) – Oppenheimer’s equity analysts released their first quarter 2024 earnings forecast for Cigna stock in a report published Thursday, Jan. 19. Oppenheimer analyst M. Wiederhorn expects his provider of health services to post earnings of $6.75 per share in the quarter. Cigna’s current consensus estimate for annual earnings is $23.13 per share. Oppenheimer also forecasts Cigna’s second-quarter 2024 earnings at $7.06 EPS, third-quarter 2024 earnings at $7.23 EPS, and fourth-quarter 2024 earnings at $6.98 EPS for fiscal year 2025. at an EPS of $31.46.
Several other research analysts have also recently published reports on stocks. Morgan Stanley raised its price target on Cigna stock from her $347.00 to her $365.00, giving it an “overweight” rating in its research report on Friday, Jan. 6. Credit Suisse Group raised its price target on Cigna stock to $368.00 from his $329.00, giving it an “outperform” rating in its research notes on Monday, November 7. Mizuho raised its price target for Cigna shares from $330.00 to $360.00 in its research report on Thursday, November 10, giving the stock a “buy” rating. Cowen raised Cigna’s target price to $385.00 from his $329.00 in a research note on Monday, November 7. Finally, Raymond James downgraded his Cigna from a ‘strong buy’ rating to an ‘outperform’ rating, and he set a price target for the company at $370.00. In an investigative report on Monday, November 21st. Eight analysts have given the stock a hold rating, 12 have issued a buy rating, and one has issued a strong buy rating to the company. According to MarketBeat.com data, the company has a consensus rating of “moderate buy” and a consensus price target of $329.45.
Cigna price performance
Cigna shares opened at $310.66 on Friday. Cigna has a 52-week low of $213.16 and a 52-week high of $340.11. The company has a market capitalization of $94.98 billion, a P/E ratio of 14.84, a P/E/G ratio of 1.13 and a beta of 0.69. The company has an equity ratio of 0.62, a quick ratio of 0.73 and a current ratio of 0.73. His 50-day moving average for this business is $321.43 and his 200-day moving average is $300.32.
Cigna (NYSE:CI – Get Rating) last reported earnings on Thursday, November 3rd. Healthcare providers reported EPS of $6.04 for the quarter, $0.34 above the consensus estimate of $5.70. The business had revenue of $45.36 billion in the quarter, compared to consensus expectations of $44.87 billion. Cigna’s return on equity was 15.94% and net profit margin was 3.67%.
Notice of Cigna Dividend
The company recently announced a quarterly dividend, which was paid out on Wednesday, December 21st. Investors of record on Tuesday, December 6 were paid a dividend of $1.12 per share. The ex-dividend date was Monday, December 5. This represents his $4.48 dividend and his 1.44% yield on an annual basis. Cigna’s payout percentage is 21.39% for him.
insider bet
In other news, insider Jason D. Sadler sold 16,667 shares in a transaction on Thursday, Dec. 8. The shares sold for an average of $333.88, and the total trading value he had was $5,564,777.96. Following the closing of the sale, insiders now own 35,750 shares of the Company’s stock valued at $11,936,210. The sale was disclosed in legal filings with the U.S. Securities and Exchange Commission, which can be accessed via this hyperlink. In other news, insider Jason D. Sadler sold 16,667 shares of the company in a transaction on Thursday, Dec. 8. The shares sold for an average of $333.88, and the total trading value he had was $5,564,777.96. Following the closing of the transaction, insiders now directly own 35,750 shares of the Company’s stock valued at $11,936,210. The transaction is disclosed in legal documents to the Securities and Exchange Commission, which can be accessed at this link. EVP Cynthia Ryan also sold 3,009 shares of Cigna stock in a transaction that took place on Friday, December 16th. The shares sold at an average price of $327.95 for a total of $986,801.55. Following the closing of the sale, the Executive Vice President now owns 4,319 shares of the company directly, valued at approximately $1,416,416.05. Please see here for the disclosure of this sale. A corporate insider owns his 0.80% of the company’s shares.
institution inflow and outflow
Several large investors have recently increased or decreased their stake in the business. Householder Group Estate & Retirement Specialist LLC purchased new shares of his Cigna stock worth approximately $34,000 in the third quarter. RFG Advisory LLC increased his Cigna stock position by 13.0% in the second quarter. RFG Advisory LLC now owns 1,697 shares of medical service provider stock valued at $478,000 after purchasing an additional 195 shares in the previous quarter. American Research & Management Co. upped his Cigna stake by 1,875.0% in the second quarter. American Research & Management Co. now owns 158 shares of the medical service provider worth $42,000 after purchasing an additional 150 shares last quarter. Creative Planning increased his Cigna stake by 3.7% in the second quarter. Creative Planning now owns 33,692 shares in the medical service provider worth $8,879,000 after he purchased an additional 1,196 shares last quarter. Finally, Exane Derivatives increased his Cigna holdings by 127.8% in the second quarter. Exane Derivatives now owns 287 shares of the healthcare provider worth $76,000 after purchasing an additional 161 shares during the previous quarter. Institutional investors and hedge funds own 87.61% of the company’s shares.
About Cigna
(get rating)
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment includes a range of coordinated point-solutions healthcare services, including pharmacies, benefits administration, care delivery and management, and intelligence solutions to healthcare planning, employers, government agencies, and healthcare providers. provide.
Related item
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.
Listen to this before considering Cigna.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Cigna wasn’t on the list. .
Cigna currently holds a ‘middle buy’ rating among analysts, but the top rated analysts believe these five stocks are the better buys.
See 5 stocks here
